Emanuel Raschi (E Raschi)

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 65

Top Venues

Drug safety

British journal of clinical pharmacology

Cancers

Immunotherapy

Università degli Studi di Bologna

Università degli Studi di Padova (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Università degli Studi di Bologna Oct 5o 2019

Italy

Associate Professor :: Department of Medical and Surgical Sciences

Education History

Università degli Studi di Padova Jan 1o 2007 - Apr 27o 2010

Italy

PHD

Publications

Charles Khouri, Michele Fusaroli, Francesco Salvo, Emanuel Raschi
Interpretation of Pharmacovigilance Disproportionality Analyses. Clinical pharmacology and therapeutics (2023)
Valentina Giunchi, Michele Fusaroli, Elkanah Linder, Johanna Villén, Björn Wettermark, Marmar Nekoro, Emanuel Raschi, Carlotta Lunghi, Elisabetta Poluzzi
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies. British journal of clinical pharmacology (2023)
Emanuel Raschi, Francesca Comito, Francesco Massari, Francesco Gelsomino
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY. Immunotherapy 15 (2) (2023)
Valentina Giunchi, Michele Fusaroli, Manfred Hauben, Emanuel Raschi, Elisabetta Poluzzi
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach. Drug safety (2023)
Emanuel Raschi, Francesca Comito, Francesco Massari, Francesco Gelsomino
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY. Immunotherapy (2023)
Emanuel Raschi, Francesca Comito, Francesco Massari, Francesco Gelsomino
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY. Immunotherapy 15 (2) (2023)
Valentina Giunchi, Michele Fusaroli, Elkanah Linder, Johanna Villén, Björn Wettermark, Marmar Nekoro, Emanuel Raschi, Carlotta Lunghi, Elisabetta Poluzzi
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies. British journal of clinical pharmacology (2023)
Francesca Menniti-Ippolito, Eugenio Aiello, Elena Arzenton, Alessandro Assisi, Urška Blaznik, Jacqueline J M Castenmiller, Marta Crevani, Dominique de Clock, Silvia Di Giacomo, Silvia Emendi, Laura Augusta Gonella, Ilaria Ippoliti, Marie Lindquist, Lara Magro, Gabriela Mazzanti, Nadia Mores, Ugo Moretti, Paola Angela Moro, Budimka Novakovic, Emanuel Raschi, Inese Siksna, Maria Rosa Valetto, Annabella Vitalone, Gwenn Vo Van Regnault
Erice Manifesto 2022: On the Surveillance of Potential Harms Caused by Food Supplements in Europe. Drug safety (2023)
Emanuel Raschi, Simone Rossi, Andrea De Giglio, Michele Fusaroli, Flavio Burgazzi, Rita Rinaldi, Luciano Potena
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians. Drug safety (2023)
Emanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
Spotlight commentary: The value of spontaneous reporting systems to detect (the lack of) clinically relevant drug-drug interactions in clinical practice. British journal of clinical pharmacology (2023)
Valentina Giunchi, Michele Fusaroli, Elkanah Linder, Johanna Villén, Björn Wettermark, Marmar Nekoro, Emanuel Raschi, Carlotta Lunghi, Elisabetta Poluzzi
The environmental impact of pharmaceuticals in Italy: integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies. British journal of clinical pharmacology (2023)
Michele Fusaroli, Arndis Simonsen, Stephanie A Borrie, Daniel M Low, Alberto Parola, Emanuel Raschi, Elisabetta Poluzzi, Riccardo Fusaroli
Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System. Journal of speech, language, and hearing research : JSLHR (2023)
Emanuel Raschi, Francesca Comito, Francesco Massari, Francesco Gelsomino
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY. Immunotherapy 15 (2) (2023)
Roberta Noseda, Laura Müller, Francesca Bedussi, Michele Fusaroli, Emanuel Raschi, Alessandro Ceschi
Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase ® Spontaneous Reporting System. Cancers 15 (1) (2022)
Emanuel Raschi, Michele Fusaroli, Valentina Giunchi, Andrea Repaci, Carla Pelusi, Veronica Mollica, Francesco Massari, Andrea Ardizzoni, Elisabetta Poluzzi, Uberto Pagotto, Guido Di Dalmazi
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System. Cancers 14 (19) (2022)
Simone Rossi, Ilaria Cani, Emanuel Raschi, Francesca Comito, Rita Rinaldi, Andrea Ardizzoni, Maria Guarino, Francesco Gelsomino
Neurological Manifestations as a Harbinger of Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Roberta Noseda, Laura Müller, Francesca Bedussi, Michele Fusaroli, Emanuel Raschi, Alessandro Ceschi
Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase ® Spontaneous Reporting System. Cancers 15 (1) (2022)
Carlotta Lunghi, Caterina Trevisan, Michele Fusaroli, Valentina Giunchi, Emanuel Raschi, Elisa Sangiorgi, Marco Domenicali, Stefano Volpato, Fabrizio de Ponti, Elisabetta Poluzzi
Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People. Pharmaceuticals (Basel, Switzerland) 15 (8) (2022)
Emanuel Raschi, Paolo Caraceni
Letter to the editor: RECAM for the diagnosis of DILI-Is it time to incorporate additional pharmacological criteria? Hepatology (Baltimore, Md.) 76 (1) (2022)
Chiara Gastaldon, E Arzenton, Emanuel Raschi, Olav Spigset, Davide Papola, Giovanni Ostuzzi, U Moretti, G Trifirò, Corrado Barbui, Georgios Schoretsanitis
Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database. Psychological medicine (2022)
Adam Goldman, Emanuel Raschi, Joab Chapman, Bianca D Santomasso, Marcelo C Pasquini, Miguel-Ángel Perales, Roni Shouval
Progressive Multifocal Leukoencephalopathy in Patients Treated With Chimeric Antigen Receptor T-Cells. Blood (2022)
Emanuel Raschi, Francesco Salvo, Charles Khouri
Conceiving, conducting, reporting, interpreting, and publishing disproportionality analyses: A call to action. British journal of clinical pharmacology 88 (7) (2022)
Michele Fusaroli, Valentina Isgrò, Paola Maria Cutroneo, Carmen Ferrajolo, Valentina Cirillo, Francesca Del Bufalo, Emanuel Raschi, Elisabetta Poluzzi, Gianluca Trifirò
Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database. Drug safety 45 (8) (2022)
Roberta Noseda, Laura Müller, Francesca Bedussi, Michele Fusaroli, Emanuel Raschi, Alessandro Ceschi
Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase ® Spontaneous Reporting System. Cancers 15 (1) (2022)
Emanuel Raschi, Michele Fusaroli, Milo Gatti, Paolo Caraceni, Elisabetta Poluzzi, Fabrizio de Ponti
Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal. Pharmaceuticals (Basel, Switzerland) 15 (5) (2022)
Emanuel Raschi, Igor Diemberger, Mario Sabatino, Elisabetta Poluzzi, Fabrizio de Ponti, Luciano Potena
Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction. Expert opinion on pharmacotherapy 23 (3) (2022)
Milo Gatti, Emanuel Raschi, Fabrizio de Ponti
Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 40 (6) (2021)
Milo Gatti, Emanuel Raschi, Ugo Moretti, Andrea Ardizzoni, Elisabetta Poluzzi, Igor Diemberger
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines 9 (1) (2021)
Emanuel Raschi, Michele Fusaroli, Igor Diemberger, Elisabetta Poluzzi
Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance. Drug safety 43 (11) (2021)
Laura Licchetta, Marina Trivisano, Elisa Baldin, Susan Mohamed, Emanuel Raschi, Barbara Mostacci, Corrado Zenesini, Manuela Contin, Federico Vigevano, Francesca Bisulli, Paolo Tinuper, Luca Vignatelli
TELEmedicine for EPIlepsy Care (TELE-EPIC): protocol of a randomised, open controlled non-inferiority clinical trial. BMJ open 11 (12) (2021)
Emanuel Raschi, Michele Fusaroli, Igor Diemberger, Elisabetta Poluzzi
Authors' Reply to Robert P. Giugliano and Colleagues' Comment on: "Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance". Drug safety 44 (4) (2021)
Milo Gatti, Michele Fusaroli, Emanuel Raschi, Ugo Moretti, Elisabetta Poluzzi, Fabrizio de Ponti
Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system. Expert opinion on drug safety 20 (11) (2021)
Emanuel Raschi, Milo Gatti, Francesco Gelsomino, Andrea Ardizzoni, Elisabetta Poluzzi, Fabrizio De Ponti
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. Targeted oncology 15 (4) (2021)
Milo Gatti, Michele Fusaroli, Emanuel Raschi, Irene Capelli, Elisabetta Poluzzi, Fabrizio de Ponti
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems. Journal of nephrology (2021)
Loris Pironi, Emanuel Raschi, Anna Simona Sasdelli
The safety of available treatment options for short bowel syndrome and unmet needs. Expert opinion on drug safety 20 (12) (2021)
Emanuel Raschi, Michele Fusaroli, Michelangelo La Placa, Andrea Ardizzoni, Claudio Zamagni, Elisabetta Poluzzi, Fabrizio De Ponti
Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System. American journal of clinical dermatology (2021)
Milo Gatti, Elisabetta Poluzzi, Fabrizio de Ponti, Emanuel Raschi
Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis. Drug safety 43 (12) (2021)
Milo Gatti, Eleonora Turrini, Emanuel Raschi, Piero Sestili, Carmela Fimognari
Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. Pharmaceuticals (Basel, Switzerland) 14 (8) (2021)
Nicolina Conti, Milo Gatti, Emanuel Raschi, Igor Diemberger, Luciano Potena
Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap. Drug design, development and therapy 15 (2021)
Emanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, Elisabetta Poluzzi, Fabrizio de Ponti
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System. Cancers 13 (8) (2021)
Marta Bellesini, Matteo Bianchin, Chiara Corradi, Marco Paolo Donadini, Emanuel Raschi, Alessandro Squizzato
Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review. Clinical drug investigation 40 (11) (2020)
Milo Gatti, Emanuel Raschi, Fabrizio de Ponti
Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis. European journal of clinical pharmacology 77 (2) (2020)
Carlotta Lunghi, Ippazio Cosimo Antonazzo, Sofia Burato, Emanuel Raschi, Violetta Zoffoli, Emanuele Forcesi, Elisa Sangiorgi, Marco Menchetti, Pasquale Roberge, Elisabetta Poluzzi
Prevalence and Determinants of Long-Term Utilization of Antidepressant Drugs: A Retrospective Cohort Study. Neuropsychiatric disease and treatment 16 (2020)
Milo Gatti, Michele Fusaroli, Paolo Caraceni, Elisabetta Poluzzi, Fabrizio De Ponti, Emanuel Raschi
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19. British journal of clinical pharmacology 87 (3) (2020)
Emanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, Elisabetta Poluzzi, Fabrizio De Ponti
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast cancer research and treatment 186 (1) (2020)
Emanuel Raschi, F Salvo, Michelangelo La Placa, E Poluzzi, F De Ponti
Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction. Journal of the European Academy of Dermatology and Venereology : JEADV 34 (8) (2020)
Emanuel Raschi, Michelangelo La Placa, E Poluzzi, F De Ponti
The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice. The British journal of dermatology 184 (3) (2020)
Emanuel Raschi, Gian Poalo Fadini, Igor Diemberger, Elisabetta Poluzzi, Fabrizio de Ponti
SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR? Expert opinion on pharmacotherapy 22 (5) (2020)
Emanuel Raschi, Matteo Bianchin, Milo Gatti, Alessandro Squizzato, Fabrizio De Ponti
Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews. Drug safety 42 (12) (2020)
Emanuel Raschi, Alessandra Mazzarella, Ippazio Cosimo Antonazzo, Nicolò Bendinelli, Emanuele Forcesi, Marco Tuccori, Ugo Moretti, Elisabetta Poluzzi, Fabrizio De Ponti
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. Targeted oncology 14 (2) (2020)
Emanuel Raschi, Paolo Caraceni, Elisabetta Poluzzi, Fabrizio de Ponti
Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19? Expert opinion on drug safety 19 (10) (2020)
Gian Poalo Fadini, Mayur Sarangdhar, Fabrizio De Ponti, Angelo Avogaro, Emanuel Raschi
Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors. BMJ open diabetes research & care 7 (1) (2019)
Ippazio Cosimo Antonazzo, Elisabetta Poluzzi, Emanuele Forcesi, Francesco Salvo, Antoine Pariente, Giulio Marchesini, Fabrizio De Ponti, Emanuel Raschi
Signal of potentially protective drug-drug interactions from spontaneous reporting systems: proceed with caution. Acta diabetologica 57 (1) (2019)
Milo Gatti, Emanuel Raschi, Fabrizio De Ponti
Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance study. BMC pharmacology & toxicology 20 (1) (2019)
Ippazio Cosimo Antonazzo, Elisabetta Poluzzi, Emanuele Forcesi, Francesco Salvo, Antoine Pariente, Giulio Marchesini, Fabrizio De Ponti, Emanuel Raschi
Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system. Acta diabetologica 57 (1) (2019)
Emanuel Raschi, Ippazio Cosimo Antonazzo, Michelangelo La Placa, Andrea Ardizzoni, Elisabetta Poluzzi, Fabrizio De Ponti
Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. The oncologist 24 (11) (2019)
Emanuel Raschi, Ippazio Cosimo Antonazzo, Elisabetta Poluzzi, Fabrizio De Ponti
Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list? Annals of the rheumatic diseases 80 (7) (2019)
Ippazio Cosimo Antonazzo, Elisabetta Poluzzi, Emanuele Forcesi, Trond Riise, Kjetil Bjornevik, Elisa Baldin, Luigi Muratori, Fabrizio De Ponti, Emanuel Raschi
Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System. Multiple sclerosis (Houndmills, Basingstoke, England) 25 (12) (2018)
Emanuel Raschi, Fabrizio de Ponti
Liver injury with direct-acting anticoagulants: has the fog cleared? Heart (British Cardiac Society) 103 (24) (2018)
Emanuel Raschi, Elisabetta Poluzzi, Gian Poalo Fadini, Giulio Marchesini, Fabrizio de Ponti
Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough? Diabetes, obesity & metabolism 20 (12) (2018)
Emanuel Raschi, Igor Diemberger, Benilde Cosmi, Fabrizio de Ponti
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations-authors' reply. Internal and emergency medicine 13 (4) (2018)
Emanuel Raschi, Anna Girardi, Elisabetta Poluzzi, Emanuele Forcesi, Francesca Menniti-Ippolito, Gabriela Mazzanti, Fabrizio De Ponti
Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems. Drug safety 41 (8) (2018)
Emanuel Raschi, Matteo Bianchin, Cecilia Fantoni, Walter Ageno, Fabrizio de Ponti, Roberto De Ponti
Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon? Internal and emergency medicine 12 (7) (2017)
Emanuel Raschi, Igor Diemberger, Benilde Cosmi, Fabrizio de Ponti
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations. Internal and emergency medicine 13 (1) (2017)
Gabriela Mazzanti, Paola Angela Moro, Emanuel Raschi, Roberto Da Cas, Francesca Menniti-Ippolito
Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system. British journal of clinical pharmacology 83 (4) (2017)

Emanuel Raschi.css-eqlu8i{font-size:small;padding-left:4px;} (E Raschi)

Publication Activity (10 Years)

Top Topics

Top Venues

Emanuel Raschi (E Raschi)